NPDRNon-Proliferative Diabetic Retinopathy
NPDRNuclear Preliminary Design Review
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Table-II shows that as the stage of diabetic retinopathy advanced from No DR to NPDR, then to PDR and advanced diabetic eye disease; the percentage of patients having severe CKD increased from 56.25% to 69.57% and then to 81.81% (p = 0.134) Among the patients giving history of receiving some ocular intervention for diabetic retinopathy; 77.78% had severe CKD, however also 64.38% of those who did not receive any diabetic retinopathy treatment were also having severe CKD (p = 0.202).
We also excluded patients with Type 1 DM, moderate-to-severe NPDR, proliferative diabetic retinopathy (PDR), or CSME cases at the time of cataract surgery, and those with a history of laser photocoagulation for macular edema.
###Individuals Screened###J Ayub Med###90-dioptre Slit###Mild NPDR =6 (35.3%)
At presentation, 13.05 % of eyes had mild NPDR, 23.62% had moderate NPDR, 8.80% had severe NPDR, 3.12 % had very severe NPDR, 16.68 % had PDR and 3.34 % had ADED.
The rest of the patients in both groups (53% of the nonmetformin group and 75% of the metformin group) were diagnosed with mild/moderate NPDR at the time of our study.
The receiver operating characteristic (ROC) curve and the corresponding area under the curve (AUC) were calculated for testing the potential of serum ecSOD activity for the identification of DR, NPDR, and PDR in T2DM patients.
The aim of this study is to compare retinal thickness in pediatric patients with type 1 diabetes mellitus (PwT1DM) diagnosed with nonproliferative diabetic retinopathy (NPDR) with those obtained in healthy subjects.
Based on clinical examination by retina specialists, subjects' eyes were classified as no DR (NDR; N = 51), nonproliferative DR (NPDR; N = 59), or proliferative DR (PDR; N = 39).
ThromboGenics NV (EBR: THR) has discontinued recruitment in its Phase II CIRCLE study for Non-Proliferative Diabetic Retinopathy (NPDR), effective immediately, due to a slow recruitment rate, the company disclosed on Friday.
ThromboGenics is conducting the CIRCLE study, a Phase II clinical trial evaluating multiple doses of THR-409 (ocriplasmin) to induce a total Posterior Vitreous Detachment in patients with Non-Proliferative Diabetic Retinopathy (NPDR).
It is classified into non-proliferative DR (NPDR) and proliferative DR (PDR).